Inactivated vaccines market seen topping $14 billion by 2030

The Business Research Company says the inactivated vaccines market is on track to surpass $14 billion by 2030, led by North America and the U.S. The report points to rising immunization demand, pandemic preparedness spending and manufacturing upgrades as the main growth drivers.

Why it matters: - The inactivated vaccines market is moving into a larger role in global drug spending as governments expand immunization campaigns and vaccine makers invest in new capacity. - The segment is forecast to exceed $14 billion by 2030, which would make it about 6% of the broader vaccines market and close to 1% of total pharmaceuticals industry value. - Growth matters because inactivated vaccines are used across routine, seasonal and travel-related immunization programs.

What happened: - The Business Research Company published its Inactivated Vaccines Global Market Report 2026, with market forecasts through 2035. - The report says North America will be the largest regional market in 2030 at $5.9 billion. - The U.S. will be the largest single-country market, reaching $5.4 billion by 2030. - The viral vaccine segment will remain the largest product type, accounting for 69% of the market, or about $10 billion, in 2030.

The details: - The global inactivated vaccines market is projected to grow from 2025 levels at a 5% compound annual growth rate through 2030. - North America is forecast to rise from $4.8 billion in 2025 to $5.9 billion in 2030. - The U.S. market is expected to increase from $4.3 billion in 2025 to $5.4 billion in 2030. - The report ties North American growth to established immunization programs, national vaccination campaigns, demand for influenza, hepatitis and travel vaccines, pandemic readiness, an aging population, manufacturing investment, cold-chain logistics and regulatory oversight. - U.S. growth is linked to adult booster uptake, disease incidence, vaccination requirements for work and travel, vaccine stockpiling, production advances and broader retail and primary-care distribution. - Inactivation methods covered in the market include solvent detergent, radiation, pH concentration, heat inactivation and others. - Distribution runs through hospital pharmacies, retail pharmacies and other outlets. - Government immunization programs and pandemic preparedness are expected to add about 1.5% annual growth. - Rising infectious disease burden is expected to add about 1.0% annual growth. - Manufacturing expansion and technical improvements are expected to add about 0.5% annual growth. - The report says viral and bacterial inactivated vaccine segments together could add more than $3 billion in market value by 2030. - The viral vaccine market is expected to grow by $2 billion between 2025 and 2030, while the bacterial segment is expected to add $1 billion. - The market includes major vaccine makers and specialized biotech firms focused on vaccine platforms, antigen production, adjuvants, scalability, safety and regulatory compliance.

Between the lines: - The market remains highly concentrated, which suggests high barriers to entry in manufacturing, regulation and quality control. - The top 10 players generated 99.9% of revenue in 2025, with Merck & Co. Inc. alone holding a 68% share. - Other leading companies include Sinopharm Group, CSL, Sanofi, GlaxoSmithKline, Pfizer, Serum Institute of India, Sinovac, Zydus Lifesciences and Valneva. - The concentration also reflects the value of large manufacturing networks, distribution reach and established immunization partnerships. - Sanofi launched Verorab, an inactivated rabies vaccine, in the UK in April 2024 for pre-exposure and post-exposure use across all age groups. - The launch points to continued innovation in next-generation inactivated vaccines and broader use in disease prevention programs.

What's next: - Companies are expected to keep investing in vaccine technologies, manufacturing efficiency, stability and research capacity. - The report expects continued demand from public health vaccination programs, infectious disease prevention and broader adoption of combination vaccines. - The Business Research Company also said its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards and hotspot visuals. - More information is available in the detailed market report and the free sample.

The bottom line: - Inactivated vaccines are a niche but expanding part of the global vaccines market, with demand anchored by immunization policy, disease burden and manufacturing scale.